



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

**Oversight Committee Meeting
May 16, 2018**

NOTE: Unless the information is confidential, the reports and presentations referenced in the minutes are available at http://www.cprit.state.tx.us/cprit-media/oc_packet_05-16-2018.pdf. Information regarding the recommended awards is available at http://www.cprit.state.tx.us/cprit-media/proposed_grant_awards_book_05162018.pdf.

Call to Order – Agenda Item 1

A quorum being present, Presiding Officer Will Montgomery called the Oversight Committee to order at 10:01 a.m.

Roll Call/Excused Absences – Agenda Item 2

Committee Members Present

Angelos Angelou
Bill Rice, M.D.
Donald (Dee) Margo
Will Montgomery
Mahendra Patel, M.D.
Craig Rosenfeld, M.D.

Adoption of Minutes from the February 21, 2018 Meeting – Agenda Item 3 – Tab 1

MOTION:

On a motion by Mr. Angelou and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the minutes of the Oversight Committee meeting of February 21, 2018, as presented.

Public Comment – Agenda Item 4

There were no requests to provide public comment.

Honorary Resolution - Amy Mitchell – Agenda Item 5 – Tab 2

Presiding Officer Montgomery presented an honorary resolution for the Oversight Committee's approval. The resolution recognized former Oversight Committee member Ms. Amy Mitchell for her years of service as an Oversight Committee member, including serving as secretary for the board.

MOTION:

On a motion made by Mr. Margo and seconded by Mr. Rice, the Oversight Committee unanimously voted to approve and sign the resolution for Ms. Mitchell.

Presiding Officer Montgomery recognized CPRIT Chief Executive Officer Wayne Roberts for a presentation to Ms. Mitchell on behalf of the CPRIT staff.

Grantee Presentation – Agenda Item 6 – Tab 3

CPRIT Chief Scientific Officer Dr. James Willson introduced Dr. James Brugarolas, Professor of Internal Medicine at The University of Texas Southwestern Medical Center (UTSW) and Director of the Harold Simmons Comprehensive Cancer Center Kidney Cancer Program.

Dr. Brugarolas reported on UTSW’s work, supported by CPRIT, to build one of the largest kidney cancer programs in the nation. His presentation included a high-level overview of the Kidney Cancer Specialized Program of Research Excellence (SPORE).

In response to an Oversight Committee member’s question on how others can export the success of the program’s survival rate - survival rates for stage 4 kidney cancer patients at UTSW are more than double the national benchmark - to clinics and communities, Dr. Brugarolas explained that his group shares their multi-disciplinary tumor board model and provides opportunities for clinicians across the state and country to present difficult cases to the group.

Internal Auditor Report – Agenda Item 16 – Tab 13

Presiding Officer Montgomery recognized CPRIT Internal Auditor Ms. Alyssa Martin, Weaver and Tidwell, LLP, to present a status update on the FY 2018 internal audit plan, the recent internal audit reports, and the reports on follow-up procedures. Ms. Martin directed members to the audit materials in the meeting packet at pages 13-1 – 13-4 and provided her report.

In response to an Oversight Committee member’s question, Ms. Martin explained that the Health Insurance Portability and Accountability Act of 1996 does not apply to any CPRIT grant information or processes.

There were no further questions for Ms. Martin.

Advisory Committee on Product Development – Agenda Item 14 – Tab 11

Presiding Officer Montgomery recognized Mr. Roberts to introduce Mr. Andrew Strong. Mr. Strong is a partner in the Houston and Austin offices of Pillsbury Winthrop. He works with several CPRIT product development applicants and grantees. Prior to joining Pillsbury, Mr. Strong was the founding president and CEO of Kalon Biotherapeutics, a 2012 CPRIT product development grantee. Fujifilm Diosynth Biotechnologies acquired Kalon in late 2014.

Mr. Strong presented the annual report on behalf of the Product Development Advisory Committee (PDAC). The PDAC report and PowerPoint presentation are included in the meeting packet at pages 11-1 – 11-20.

Following Mr. Strong's presentation, an Oversight Committee member inquired about whether there is any interaction between product development applicants and the review committee during the due diligence phase of the grant application review process. Mr. Strong replied that there is little interaction, if any, at this stage. CPRIT General Counsel Kristen Doyle commented that if CPRIT were to make changes in this area, the agency would need to develop and implement a new process. Another Oversight Committee member remarked that if CPRIT were to put such a process in place, all applicants would need equal access to the review committee in the due diligence phase to ensure a level playing field.

An Oversight Committee member asked Mr. Strong about whether it is better to provide larger amounts of funding to more-developed projects or smaller amounts of funding to earlier stage projects. Mr. Strong replied that the amount of funding depends on the development stage of the project. He explained that the biggest costs for these companies are clinical trials and manufacturing, so larger awards are more important to applicants that are seeking funding for Phase 1 and 2 clinical trials. Mr. Strong reported that companies are also excited about the new Seed Award program. The Seed Award will help fund early preclinical studies to help the companies get to the point where their project is more attractive to external investors.

An Oversight Committee member asked whether companies are more likely to attract investment at the later stages of development. Mr. Strong replied that typically big pharma is not interested until companies complete their Phase 2 clinical efficacy studies.

An Oversight Committee member asked whether smaller funding amounts (such as the amount offered through the Seed Award program) would help companies obtain experienced leadership. Mr. Strong replied that he does not believe that early stage companies will attract a CEO to relocate from Boston, for example, with a \$3M grant. Small funding awards, Mr. Strong explained, would go mostly towards further developing the technology, not attracting experienced management teams. Mr. Strong elaborated that the Seed Award could be useful when institutions such as MD Anderson or Baylor College of Medicine have a molecule that they want to put into a company. An accelerator could run that company, for example.

Advisory Committee on Childhood Cancer (ACCC) - Annual Report – Agenda Item 13 – Tab 10

Dr. Willson introduced Dr. Susan Blaney, Chair of the Advisory Committee on Childhood Cancer (ACCC). Dr. Blaney is Professor of Pediatrics at Baylor College of Medicine and serves as Executive Vice Chair of the Department of Pediatrics and as Deputy Director Center and Hematology Center, Texas Children's Hospital. Dr. Willson noted that Dr. Blaney has provided outstanding guidance and support to CPRIT through her membership and leadership of the ACCC.

Dr. Blaney presented the ACCC 2017 annual report and recommendations to the Oversight Committee (pages 10-1 – 10-42 in the meeting packet) and provided an overview of the ACCC's mission.

Following her presentation, an Oversight Committee member asked about the impact of CPRIT Childhood Cancer Awards to date. Dr. Blaney responded that impact has been significant. She noted that the success rate of applications devoted to childhood and adolescent cancers has increased from 4% in 2014 to 24% in 2017. Dr. Blaney explained that the impact of the awards

funded by CPRIT is tremendous since the life-years for survivors of childhood cancer exceeds that of their adult counterparts significantly. She suggested CPRIT may measure evidence of success by publications and new grant dollars from the NIH and other peer reviewed sources.

Chief Executive Officer Report – Agenda Item 7 – Tab 4

Presiding Officer Montgomery recognized Mr. Roberts for the CEO report.

Mr. Roberts reported that if the Oversight Committee approves all recommendations presented at the meeting, there will be \$170 million in available grant funds for the rest of the year.

After providing a personnel update, Mr. Roberts gave an overview of two recent CPRIT outreach events. On May 1, 2018, Mr. Montgomery delivered the lunch keynote at the Texas Healthcare & Bioscience Institute Annual Summit. The Houston City Council held its National Cancer Research Month Proclamation event held May 15, which was well attended by CPRIT staff and Houston area grantees. Mr. Roberts thanked staff members Chris Cutrone and Spencer Miller-Payne for working with the Houston City Council for this occasion.

Mr. Roberts reported that he and CPRIT's Chief Product Development Officer Michael Lang will attend the BIO conference in a few weeks in Boston and will have meetings with interested companies at the conference.

There were no questions for Mr. Roberts.

Chief Compliance Officer Report – Agenda Item 8 – Tab 5

Mr. Vince Burgess, Chief Compliance Officer, presented his compliance program update (in the meeting packet beginning at page 5-1) on the status of required grantee reports, second-level reviews of financial status report, single audit tracking, desk reviews, onsite visits, annual compliance attestations, and trainings.

Mr. Burgess directed Oversight Committee members to the chart on page 5-5 in the meeting packet. He noted that the dotted line indicated a 5% non-compliance threshold for the approximately 570 reports submitted every month. Overall, delinquent reporting for FY18 has been under 5% threshold, except for January. Mr. Burgess reminded Oversight Committee members that at the February 2018 meeting he discussed recent changes to CPRIT's grants management system that led to the increase in the number of delinquent reports.

Mr. Burgess also informed the Oversight Committee members CPRIT is instituting a change so that the Single Audit Determination (SAD) form will be submitted for each institution via email annually. The SAD form is used to certify whether a grantee has expended \$750,000 or more in state awards. Previously the grantee submitted the form through the grants management system for each active grant separately; this was an administrative burden for grantees. This new process will allow CPRIT to collect information at the grant level.

Mr. Burgess noted that CPRIT staff conducted a grantee training webinar on March 7, 2018, with 190 grantee staff in attendance. Also, CPRIT compliance staff was invited to make a training

presentation at the National Council of University Research Administrators Region V conference on May 8 in San Marcos.

There were no questions for Mr. Burgess.

Compliance Investigation Pursuant to Health & Safety Code 102.2631 – Agenda Item 24 Consultation with General Counsel – Agenda Item 25

At 11:50 a.m. Presiding Officer Montgomery called the Oversight Committee into closed session to discuss agenda items 24 and 25 pursuant to the Texas Open Meeting Act § 551.074, and Texas Health & Safety Code § 102.2631 to discuss an ongoing compliance investigation and to receive advice from counsel. Mr. Montgomery asked Ms. Doyle, Mr. Roberts, Mr. Burgess, and Dr. Willson to join the Oversight Committee in the closed Session.

Mr. Montgomery reconvened the open meeting at 12:47 p.m. The Oversight Committee did take any action.

Future Meeting Dates and Agenda Items – Agenda Item 26

Presiding Officer Montgomery reminded members that the Oversight Committee will hold its next regular meeting on August 15, 2018.

He also noted that the regularly scheduled November meeting date will conflict with the Thanksgiving holiday. He advised members that the Oversight Committee will meet either November 28 or 29 instead. Mr. Roberts will coordinate with individual members regarding their schedules and update the Oversight Committee with the final date.

Chief Scientific Officer Report – Agenda Item 9 – Tab 6

Academic Research Award Recommendations

Presiding Officer Montgomery recognized Dr. Willson to present the academic research award slates recommended by the CPRIT Scientific Review Council (SRC) and the Program Integration Committee (PIC). Dr. Willson presented the eight recruitment grant awards recommended by the SRC and the PIC totaling \$29,986,494. He provided a summary of each of the four Established Investigator candidates and four First-Time Tenure Track Faculty candidates.

Compliance Certification (Academic Research and Prevention Awards)

Mr. Burgess presented his certification of the review process for the proposed grant awards recommended to the Oversight Committee (included in the proposed grant awards packet at pages 47 - 51). He reviewed the compliance pedigrees for the grant applications submitted to CPRIT for the seven academic research award mechanisms and four prevention award mechanisms.

Conflict of Interest Notification

Presiding Officer Montgomery noted that Mr. Angelou reported a conflict of interest with grant application RR180034 submitted by The University of Texas at Austin.

Presiding Officer Montgomery suggested that, unless a member objected, the Oversight Committee consider all the academic research award recommendations together in one vote except for the proposed award to The University of Texas at Austin, which the committee would vote on separately. No member objected.

Rank	App ID	Candidate	Mechanism	Organization	Budget	Overall Score
1	RR180025	Sheetz, Michael	REI	The University of Texas Medical Branch at Galveston	\$6,000,000	1.0
2	RR180029	Sung, Patrick	REI	The University of Texas Health Science Center at San Antonio	\$6,000,000	1.0
3	RR180035	Shen, John	RFTFM	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	1.3
4	RR180046	Chung, Stephen	RFTFM	The University of Texas Southwestern Medical Center	\$2,000,000	1.6
5	RR180040	Xiao, Xinshu	REI	Baylor College of Medicine	\$4,000,000	1.8
6	RR180044	Yi, Qing	REI	The Methodist Hospital Research Institute	\$5,986,494	2.2
7	RR180034	Powers, John	RFTFM	The University of Texas at Austin	\$2,000,000	2.2
8	RR180041	Musah, Samira	RFTFM	Rice University	\$2,000,000	2.3

RRS: Recruitment of Established Investigators

RFTFM: Recruitment of First-Time Tenure Track Faculty Members

* In response to an Oversight Committee member's question about scoring applications, Dr. Willson noted that the SRC considers the qualification of the candidate, the institutional commitment, and the prospects that the recruitment will lead to a significant impact on cancer.

MOTION:

On a motion made by Dr. Rosenfeld and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the PIC's recommendations for The University of Texas at Austin grant application RR180034.

Presiding Officer Montgomery noted for the record that Mr. Angelou did not vote on these recommendations.

MOTION:

On a motion made by Mr. Margo and seconded by Mr. Rice, the Oversight Committee unanimously voted to approve the PIC's recommendations for the remaining seven Recruitment Awards.

MOTION:

On a motion made by Mr. Margo and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the delegation of contract negotiation authority to the Chief Executive Officer and CPRIT staff and authorized the Chief Executive Officer to sign the contracts on behalf of CPRIT.

Academic Research Program Report

Dr. Willson presented his report (pages 6-1 to 6-7 in the meeting packet).

Proposed Plan for RFAs for FY 2019 Cycle 2

Dr. Willson noted the Academic Research Program is proposing an additional RFA for FY 2019 Cycle 2 as discussed at Oversight Committee's February meeting. He provided a high-level overview of the proposed RFA, "Collaborative Action Program to Reduce Liver Cancer Mortality in Texas." Dr. Willson noted that CPRIT convened a group of thought leaders in liver cancer early in May whom collectively provided input and guidance that CPRIT will reflect in the RFA.

An Oversight Committee member asked if the funding for the project (\$18M) was sufficient. Dr. Willson responded that the funding alone was not enough to fully address the epidemic of hepatocellular cancer in Texas, but he noted that the funding will support important dissemination and implementation research and will be a strong catalyst to generate additional funds from the federal government and charitable foundations to continue the promising research projects.

In response to a question regarding the operational aspects of the proposed Center for Collaborative Action, Dr. Willson stated the Center's purpose is not as a coordination center, but as a hub for promoting collaborations across the research projects, dissemination of findings, and outreach to promote uptake of screening guidelines by physicians and community practice health systems.

MOTION:

On a motion made by Mr. Margo and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the Academic Research Program's plan for proposed RFAs for the second cycle of FY 2019.

Delegation of Contract authority for RP150058

Mr. Roberts and Dr. Willson presented a request for a delegation of authority to replace the primary investigator and approved continued disbursement of funds for grant RR150058.

MOTION:

On a motion made by Mr. Angelou and seconded by Mr. Margo, the Oversight Committee unanimously voted to delegating authority to CPRIT's CEO to approve replacing the primary investigator on grant RR150058 and to contribute distributing grant funds according to a plan and budget approved by Mr. Roberts.

Chief Prevention and Communications Officer Report – Agenda Item 10 – Tab 7

Communications Report

Dr. Garcia reported on Communications activities (pages 7-4 – 7-38 in the meeting packet). She shared a slide and videos highlighting three notable pieces of coverage.

- Governor Abbott tweeted about a Dallas Morning News article announcing CPRIT’s new Company Seed Grant Award.
- In a video clip, Governor Abbott thanked THBI for their work and in it recognized CPRIT’s work.
- A press conference held in April at Texas Tech El Paso to announce the Recruitment of CPRIT Scholar Dr. Gadad resulted in 11 different news items on television and in print.

In other activities, Chris Cutrone, Spencer Miller-Payne, and Wayne Roberts attended the City of Houston Proclamation event recognizing National Cancer Research month on May 15, 2018. Mr. Cutrone worked with the City of Houston and CPRIT grantee institutions to plan and coordinate the event.

There were no questions for Dr. Garcia.

Prevention Award Recommendations

Presiding Officer Montgomery recognized Dr. Garcia to present the Prevention Review Council (PRC) and PIC’s recommendations for prevention awards and to provide the prevention program update. She reported that the PRC and PIC recommended one “Dissemination of CPRIT Funded Cancer Control Interventions” project for \$300,000. Dr. Garcia reported that the recommended application addresses one or more of the Prevention Program priorities.

Prevention Grant Award Recommendations – Dissemination Cycle 18.3

App. ID	Mech	Application Title	PD	Organization	Score	Rank Order	Budget
PP180110	DI	Training CHWs to disseminate culturally competent, family health history-based cancer prevention and navigation services among Chinese Americans	Chen, Lei-Shih	Texas A&M University	2.0	1	\$300,000

DI: Dissemination of CPRIT-Funded Cancer Control Interventions

An Oversight Committee member questioned which ten Texas counties had the highest Chinese American population. CPRIT Senior Director for Prevention Programs Ramona Magid provided the information to the member immediately after the meeting. The ten counties are Harris, Fort Bend, Collin, Dallas, Travis, Tarrant, Bexar, Denton, Williamson, and Brazos counties.

Compliance Certification

Presiding Officer Montgomery noted that Mr. Burgess previously certified compliance of the prevention awards process.

Conflict of Interest Notification

Presiding Officer Montgomery noted that no Oversight Committee member reported a conflict of interest with the applications under consideration.

MOTION:

On a motion made by Mr. Angelou and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the PIC's recommendations for one Dissemination of CPRIT-Funded Cancer Control Intervention award.

MOTION:

On a motion made by Dr. Rice and seconded by Dr. Patel, the Oversight Committee unanimously voted to approve the delegation of contract negotiation authority to the Chief Executive Officer and CPRIT staff and authorized the Chief Executive Officer to sign the contract on behalf of CPRIT.

Chief Product Development Officer Report – Agenda Item 11 – Tab 8

Mr. Roberts presented the Product Development program update on behalf of Mr. Lang, whom was unable to attend the Oversight Committee meeting.

There were no questions for Mr. Roberts.

Scientific Research and Prevention Program Committee Appointments – Agenda Item 12 – Tab 9

Presiding Officer Montgomery recognized Mr. Roberts to present one appointee to CPRIT's Scientific Research and Prevention Program Committee. Mr. Roberts recommends the appointment to the peer review committees for Oversight Committee approval. He noted that CPRIT provided the biographical information for the appointee in the meeting packet (pages 9-1 - 9-10) and that the Nominations Subcommittee discussed the appointment at their May 11, 2018, subcommittee meeting and recommends approval.

There were no questions for Mr. Roberts.

MOTION:

On a motion by Dr. Rosenfeld and seconded by Mr. Angelou, the Oversight Committee unanimously voted to approve the Scientific Research and Prevention Program Committee appointment.

Advisory Committee on Clinical Trials – Agenda Item 15 – Tab 12

Mr. Roberts and Dr. Willson presented the Advisory Committee on Clinical Trials Charter.

MOTION:

On a motion made by Mr. Angelou and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the creation and charter of the Clinical Trials Advisory Committee.

Mr. Roberts and Dr. Willson presented the inaugural members of the Advisory Committee on Clinical Trials for the Oversight Committee's consideration.

MOTION:

On a motion made by Dr. Patel and seconded by Mr. Angelou, the Oversight Committee unanimously voted to approve the proposed members of the Clinical Trials Advisory Committee.

Oversight Committee Secretary Position – Agenda Item 17

Presiding Officer Montgomery informed that Oversight Committee members that with the resignation of Ms. Amy Mitchell the position of Secretary was now vacant. He requested that Dr. Patel fill this position until the next election of Oversight Committee officers in 2019. Dr. Patel accepted.

MOTION:

On a motion by Dr. Rosenfeld and seconded by Dr. Rice, the Oversight Committee unanimously voted to appoint Dr. Patel as Secretary of the Oversight Committee.

Health & Safety Code Section 102.1062 Waiver – Agenda Item 18 – Tab 14

Mr. Roberts presented a conflict of interest waiver related to review council members pursuant to Texas Health & Safety Code Section 102.1062. The waiver request is included in the meeting packet at Tab 14.

In response to a question from the Oversight Committee, Ms. Doyle clarified that even with the waiver in place, the review council member cannot discuss or advocate for the individual application with which he or she has the conflict. However, approving the waiver will allow the review council member to take part in a discussion and vote involving all grants considered by the panel, even if the application that gives rise to the conflict is part of the larger group of awards. She explained that usually this will occur when the panel is discussing the panel's overall award recommendations.

MOTION:

On a motion made by Dr. Rice and seconded by Dr. Rosenfeld, the Oversight Committee unanimously voted to approve the proposed Health & Safety Code Section 102.1062 waiver.

Amendments to 25 T.A.C. Chapters 701 - 703 – Agenda Item 19 – Tab 15

Presiding Officer Montgomery recognized CPRIT Staff Attorney Ms. Cameron Eckel to present the rule changes for Oversight Committee Action. Ms. Eckel referred members to the final rule changes and proposed amendments in the meeting packet at pages 15-1 – 15-30. She reported that

the Board Governance subcommittee recommended final approval for amendments to Texas Administrative Code Chapter 701 and 703, originally considered by the Oversight Committee at the February 2018 meeting. In addition, Ms. Eckel reported that the Board Governance subcommittee recommended that the Oversight Committee approve publication in the *Texas Register* of three proposed rule changes to Texas Administrative Code Chapters 701 and 703.

MOTION:

On a motion by Dr. Rice and seconded by Mr. Margo, the Oversight Committee unanimously voted to approve the final orders adopting rules changes to the Texas Administrative Code Chapters 701 and 703 and to approve the publication of the proposed changes to the Texas Administrative Code Chapters 701 and 703 in the *Texas Register*.

Fiscal Year 2019 Bond Issuance Resolution – Agenda Item 20 – Tab 16

Presiding Officer Montgomery called upon Ms. Heidi McConnell, Chief Operating Officer, to present the staff recommendation and resolution in the meeting packet at pages 16-1 – 16-7. She reported that CPRIT is requesting the Texas Public Finance Authority to issue debt on behalf of CPRIT in FY 2019. The \$300 million in bond proceeds is appropriated to CPRIT for its operations and prevention and research grant awards.

MOTION:

On a motion by Mr. Angelou and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the bond issuance resolution requesting that the Texas Public Finance Authority issue debt on behalf of CPRIT in FY 2019.

Chief Operating Officer Report – Agenda Item 21 – Tab 17

Presiding Officer Montgomery asked Ms. McConnell to present the Chief Operating Officer's report. Ms. McConnell reported on the operating budget, performance measures, debt issuance history for the second quarter of Fiscal Year 2018, State Agency Strategic Planning for the 2018 – 2019 biennium, and CPRIT's Legislative Appropriations Request (LAR) for the 2020 – 2021 budget, noting that the information is in the meeting packet at pages 17-1 – 17-14.

Ms. McConnell noted that the LAR is due before the next regular meeting Oversight Committee scheduled for August. She requested that the Oversight Committee provide preliminary approval now and designate the Audit Subcommittee to review the final draft prior to submission to confirm that the items presented are consistent with LAR request items as listed in the meeting packet at pages 17-13 – 17-14 the Oversight Committee.

In response to a question from the Oversight Committee, Ms. McConnell explained that after the Oversight Committee approves the 2020-21 LAR, it is submitted to Legislature and Governor for consideration during the next legislative session that begins January 2019.

MOTION:

On a motion by Mr. Angelou and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the draft Legislative Appropriations Request, subject to final review by the Audit subcommittee.

Contract Approvals – Agenda Item 22 – Tab 18

Ms. McConnell presented five contracts that staff recommends CPRIT award. Three memos explaining the contract needs are in the meeting packet at pages 18-1 – 18-6. She noted for the record that no Oversight Committee members and CPRIT staff reported financial conflicts with any of the firms that CPRIT intends to enter into a contract. The contracts recommended for award include:

- Due Diligence Support Services Contract with ICON Clinical Research for \$212,200
- Grant Management Support Services Contract Renewal with CSRA for \$8,400,443
- Outside Counsel Contracts for legal services to prepare intellectual property due diligence reviews as well as revenue sharing agreements:
 - Vinson & Elkins, LLP for \$125,000
 - Baker Botts, LLP for \$125,000
 - Yudell Isidore, LLP for \$125,000

MOTION:

On a motion by Mr. Angelou and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve contracts with ICON, CSRA, Baker Botts, Vinson & Elkins, and Yudell Isidore.

Subcommittee Business – Agenda Item 23


There was no discussion or action on this standing agenda item.

Adjourn – Agenda Item 27

MOTION:

There being no further business, the Oversight Committee unanimously approved a motion to adjourn made by Presiding Officer Montgomery and seconded Dr. Rosenfeld.

Meeting adjourned at 1:59 p.m.



Signature

5/24/18

Date



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

Will Willson
5/16/18
Wayne R. Roberts
5/16/18

May 3, 2018

Dear Oversight Committee Members:

I am pleased to present the Program Integration Committee's (PIC) unanimous recommendations for funding nine grant applications totaling \$30,286,494. The PIC recommendations for eight academic research grant awards and one prevention award are attached.

Dr. Jim Willson, CPRIT's Chief Scientific Officer, and Dr. Becky Garcia, CPRIT's Chief Prevention Officer, have prepared overviews of the academic research and prevention slates to assist your evaluation of the recommended awards. The overviews are intended to provide a comprehensive summary with enough detail to understand the substance of the proposal and the reasons endorsing grant funding. In addition to the full overviews, all of the information considered by the Review Councils is available by clicking on the appropriate link in the portal. This information includes the application, peer reviewer critiques, and the CEO affidavit for each proposal.

The approval of these grant recommendations is governed by a statutory process that requires two-thirds of the members present and voting to approve each recommendation. Vince Burgess, CPRIT's Chief Compliance Officer, will certify that the review process for the recommended grants followed CPRIT's award process prior to any Oversight Committee action.

The award recommendations will not be considered final until the Oversight Committee meeting on May 16, 2018. Consistent with the non-disclosure agreement that all Oversight Committee members have signed, the recommendations should be kept confidential and not be disclosed to anyone until the award list is publicly announced at the Oversight Committee meeting. I request that Oversight Committee members not print, email or save to your computer's hard drive any material on the portal. I appreciate your assistance in taking all necessary precautions to protect this information.

If you have any questions or would like more information on the review process or any of the projects recommended for an award, CPRIT's staff, including myself, Dr. Willson, and Dr. Garcia are always available. Please feel free to contact us directly should you have any questions. The programs that will be supported by the CPRIT awards are an important step in our efforts to mitigate the effects of cancer in Texas. Thank you for being part of this endeavor.

Sincerely,
Wayne R. Roberts
Chief Executive Officer

Academic Research Award Recommendations –

The PIC unanimously recommends approval of eight academic research grant proposals totaling \$29,986,494. The recommended grant proposals were submitted in response to two grant mechanisms: Recruitment of First-Time, Tenure-Track Faculty Members; and Recruitment of Established Investigators. The SRC provided the prioritized list of recommendations for the Recruitment awards to the presiding officers on April 23, 2018.

The PIC is required to give funding priority, to the extent possible, to applications that meet one or more criteria set forth in V.T.C.A., TEX. HEALTH & SAFETY CODE § 102.251(a)(2)(C). The PIC determined that these academic research proposals met the following CPRIT funding priorities:

- could lead to immediate or long-term medical and scientific breakthroughs in the area of cancer prevention or cures for cancer;
- strengthen and enhance fundamental science in cancer research;
- ensure a comprehensive coordinated approach to cancer research and cancer prevention;
- are interdisciplinary or interinstitutional;
- address federal or other major research sponsors' priorities in emerging scientific or technology fields in the area of cancer prevention or cures for cancer;
- are matched with funds available by a private or nonprofit entity and institution or institutions of higher education;
- are collaborative between any combination of private and nonprofit entities, public or private agencies or institutions in this state, and public or private institutions outside this state;
- have a demonstrable economic development benefit to this state;
- enhance research superiority at institutions of higher education in this state by creating new research superiority, attracting existing research superiority from institutions not located in this state and other research entities, or enhancing existing research superiority by attracting from outside this state additional researchers and resources; and
- address the goals of the Texas Cancer Plan.

Academic Research Recruitment Grant Award Recommendations

Rank	Application ID	Candidate	Mech.	Organization	Budget	Overall Score
1	RR180025	Sheetz, Michael	REI	The University of Texas Medical Branch at Galveston	\$6,000,000	1.0
2	RR180029	Sung, Patrick	REI	The University of Texas Health Science Center at San Antonio	\$6,000,000	1.0
3	RR180035	Shen, John	RFTFM	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	1.3
4	RR180046	Chung, Stephen	RFTFM	The University of Texas Southwestern Medical Center	\$2,000,000	1.6
5	RR180040	Xiao, Xinshu	REI	Baylor College of Medicine	\$4,000,000	1.8
6	RR180044	Yi, Qing	REI	The Methodist Hospital Research Institute	\$5,986,494	2.2
7	RR180034	Powers, John	RFTFM	The University of Texas at Austin	\$2,000,000	2.2
8	RR180041	Musah, Samira	RFTFM	Rice University	\$2,000,000	2.3

REI: Recruitment of Established Investigators

RFTFM: Recruitment of First-Time Tenure Track Faculty Members

Prevention Award Recommendation –

The PIC unanimously recommends approval of one prevention grant proposal totaling \$300,000. The recommended grant proposal was submitted in response to the following mechanism: Dissemination of CPRIT-Funded Cancer Control Interventions. The Prevention Review Council (PRC) provided its recommendation to the presiding officers on April 13, 2018.

The PIC is required to give funding priority, to the extent possible, to applications that meet one or more criteria set forth in V.T.C.A., TEX. HEALTH & SAFETY CODE § 102.251(a)(2)(C). The PIC determined that the prevention proposal met the following CPRIT funding priorities:

- ensure a comprehensive coordinated approach to cancer research and cancer prevention;
- are interdisciplinary or interinstitutional;
- are collaborative between any combination of private and nonprofit entities, public or private agencies or institutions in this state, and public or private institutions outside this state;
- have a demonstrable economic development benefit to this state; and
- address the goals of the Texas Cancer Plan.

Prevention Grant Award Recommendations

App. ID	Mech.	Application Title	PD	Organization	Score	Rank Order	Budget
PP180110	DI	Disseminating Cancer Control Framework and Strategies, a UT System Partnership	Chen, Lei-Shih	Texas A&M University	2.0	1	\$300,000

DI: Dissemination of CPRIT-Funded Cancer Control Interventions